2-cyclopropylimidazo[1,2-b]pyridazine | 1421786-86-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: 2-cyclopropylimidazo[1,2-b]pyridazine
• CAS: 1421786-86-8
• 化学式: C₉H₉N₃
• 分子量: 159.191
• InChiKey: BTHAWDQJAOYKCF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  30.2
• 氢给体数：
  0
• 氢受体数：
  2

文献信息

• 2-OXO-1-PYRROLIDINE DERIVATIVES
  申请人：Kenda Benoit

  公开号：US20090156607A1

  公开（公告）日：2009-06-18

  The present invention concerns 2-oxo-1-pyrrolidine derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals.

  本发明涉及2-氧代-1-吡咯烷衍生物、其制备过程、含有它们的药物组合物及其作为药物的用途。
• Imidazopyridazine compounds
  申请人：Pfizer Inc.

  公开号：US10669279B2

  公开（公告）日：2020-06-02

  The present invention is directed to compounds of Formula I: or a pharmaceutically acceptable salt thereof, wherein the substituents R1, R3, R6, R7, and b are as defined herein. The invention is also directed to pharmaceutical compositions comprising the compounds, methods of treatment using the compounds, and methods of preparing the compounds.

  本发明涉及式 I 的化合物： 或其药学上可接受的盐，其中取代基 R1、R3、R6、R7 和 b 如本文所定义。本发明还涉及包含这些化合物的药物组合物、使用这些化合物的治疗方法以及制备这些化合物的方法。
• DIBENZOOXEPIN DERIVATIVE
  申请人：Kyowa Hakko Kirin Co., Ltd.

  公开号：EP2740730B1

  公开（公告）日：2016-11-16
• Imidazopyridazine Compounds
  申请人：Pfizer Inc.

  公开号：US20180346475A1

  公开（公告）日：2018-12-06

  The present invention is directed to compounds of Formula I: or a pharmaceutically acceptable salt thereof, wherein the substituents R 1 , R 3 , R 6 , R 7 , and b are as defined herein. The invention is also directed to pharmaceutical compositions comprising the compounds, methods of treatment using the compounds, and methods of preparing the compounds.
• IMIDAZOPYRIDAZINE COMPOUNDS
  申请人：Pfizer Inc.

  公开号：US20190322674A1

  公开（公告）日：2019-10-24

  The present invention is directed to compounds of Formula I: or a pharmaceutically acceptable salt thereof, wherein the substituents R 1 , R 3 , R 6 , R 7 , and b are as defined herein. The invention is also directed to pharmaceutical compositions comprising the compounds, methods of treatment using the compounds, and methods of preparing the compounds.